瑞博生物-B2025年报

（於中華人民共和國註冊成立的股份有限公司） 2025年報 29111415285181841132025174179180181183185187 1.00 168 1526 24840 H 183171712-1716 97927 www.ribolia.com 117 2581101501-508601-604 6938 2025BDvortosiran(RBD4059)2RBD50442RBD702223Madrigal44siRNA20261921 XIFXIvortosiran(RBD4059)2a20251vortosiranFXI90%FXI(Best-in-Class)C3APOC3RBD504422026129PCSK9RBD7022(QLC7401)33HDVRBD1016EMA (First-in-Class)Best-in-Class RiboGalSTARTMGalNAc2025RiboPepSTARTMsiRNAFirst-in-ClassBest-in-Class 202520262MASHMadrigal44RiboGalSTAR™MASHsiRNA 20251.4854.1%20241.6794.0672.8052024 2026vortosiranRBD5044 siRNA 20261 920232023 6120071182017912025318(i)2012(ii)2013(iii)2016(iv)2021RiboAustralia(v)2022RibocureAB(vi)2023 35200612017820172020 (i)2021620233Lepton Pharmaceuticals Inc.(ii)201911202111(iii)2017820207000710(iv)2013120194(v)2011320173(vi)201211202010(vii)2009720179(viii)201011201511(ix)200210200512 (i)201411(ii)20101 198571988619951019981120109 56202211202212023720237142025318202632520222Ribocure AB AstraZeneca ABAstraZeneca PlcAstraZeneca PlcAZNAZN20(i)20194202112(ii)2019120194(iii)2018620194(iv)2013820194(v)2011920137(vi)20071020112(vii)2001320079 1997620009200092008 5920071182007420074202072020720216202162025318(i)201210(ii)20158(iii)2017820212202162021620237(iv)20216RiboAustralia(v)20222RibocureAB(vi)20257(vii)20255 (i)2021420237(ii)1999 198871996619981120102003Stiftelsen SkapaSkapa 4320217202025318 200710201032011220149201862022730101520193202112202172023920211220231120222202311 (i)2021420141220214(ii)201811(iii)20194(iv)20196(v)20196(vi)20211(vii)20216(viii)20221(ix)20238(x)20239(xi)2025813(xii)20259 20046201012 3820181018202531820191 2011820152 20222202566990 20097201172024720158 5620191182025318201912 25199720002611601211 (i)20102(ii)20231(iii)202310(iv)20207(v)202311Easy-Logic Technology Holding Cayman Limited2020620255 1991719977201672018920172024TOP10020242024 6220207162025318 198871991619961019985IBEXTechnologies IncIBT1998520104Sanofi Pasteur Limited2009168818506185OTC Pink Open MarketCASBF 198571988619986(i)20134(ii)2010 2 5320207162025318 25199910201510199791999920091200942014120188201412014120188(i)2011520174000151(ii)2014120206 002662(iii) 201312202110300663(iv)20205202010688282(v)201811202412601611(vi)2020520255600480 20009201511202110(i)20226(ii)20233(iii)20238002049(iv)20262300270 199471997719999200052006120125 6320253182025515 DABANC HOLDING LIMITED2019420061TDR Capital International Ltd. 198361986620172018 43200744200742010520106201512201612018320184202352023520201027 2006720073600664 20067 4420207 16 20144201532010620144 201532018120247 200472007720123 3620207 162014620244 201272012968816620121020136201362014400246420226 28 201262023120193 59 612016425201642022320223201912CMC 19886199291992919979(GeorgiaInstituteofTechnology)19971020003CytRx CorporationCYTR2000420017Solvay Pharmaceuticals, Inc.2001820164Pfizer Inc.PFE 20151201512(ISPE)20131201412 198571988619979 6020131120131202042020420224 19907199381994101998819989200111200011200111200412009122010120121220091020149201510(Journal of Oral Pathology& Medicine)20189 198771990720045 482024121202522025420251217 202000720041120041220057200612Exane BNP Paribas UK20136201522015420161220198201982021116855202111202411 2 0 0 072 0 0 79( H E CSchool of Management)20077 Anders Gabrielsen5920263 252023 Gabrielsen20Gabrielsen1994•2003(DMSc)2003201120112023GabrielsenBayer AGNovartis AG AstraZeneca PLC John Taylor5620263 252023 Taylor20Taylor1991DNA19911993DNA19932003TaylorPfizer Inc.20042023TaylorAstraZenecaPLC2004201120112023 20251217 202512 17 20 20262300270 20263252026325 13.51B(1) 2007siRNARNAsiRNA RNA(RNAi)CMCNGalNAcsiRNARiboGalSTARTMsiRNARiboGalSTARTMGalNAc-siRNAASGPR RiboGalSTARTM(MNC)RNAiRiboOncoSTAR™RiboPepSTAR™siRNA GalNAcRiboGalSTARTMsiRNA 20INDCTA siRNA20231220262Madrigal44RiboGalSTAR™ GalNAcRiboGalSTARTMsiRNARNA 1.MASHHAENAION 2.202312RBD7022RBD7022siRNA 3.RBD7007RBD2080 vortosiran (RBD4059)2a 5.EMARBD50442CTA2024102202512026220262 6.RBD1016CHB2MRCT202510RBD1016 7.RBD1016CHD2a202482026 siRNA20 RBD4059 (vortosiran)siRNA vortosiransiRNAFXIsiRNAvortosiranRiboGalSTAR™1,000DOACvortosiranFXIsiRNA vortosiranFXIsiRNAvortosiran 202410vortosiran120245EMACTA20248vortosiran2a2a(SPAF)2bCTAEMA 2025ESCvortosiranFXIFXI 20262Blood Advancesvortosiran1vortosiranFXI90%vortosiranFXI FXIFXIFXI50 mg150 mg400 mg 600 mg67.5%81.0%85.8%91.6%16916945.3%62.3%74.3%83.5% VORTOSIRAN RBD5044APOC3HTGsiRNA RBD5044APOC3siRNAAPOC3HTGHTGAPOC3 RBD5044APOC3siRNARBD5044APOC3RBD5044RBD50442025ESCRBD50441RBD50441RBD5044APOC384%TG70%50%70%ApoB20%HDL40%RBD5044 RBD5044RBD5044 202410RBD50441EMA220246301PK220261INDRBD5044220262 RBD5044 RBD7022PCSK9siRNA RBD7022PCSK9siRNARNARBD7022PCSK9LDL(LDL-R)LDL24PCSK9siRNA RBD7022InclisiranLDL-CInclisiranPCSK9siRNA2025ESCRBD70221RBD7022InclisiranLDL-CPCSK9RBD7022PCSK975% 202312RBD7022RBD7022siRNA RBD702212023520253RBD70222(LPLD)3IDNCT07441317 RBD7022 RBD7007RBD2080 siRNAC